Format

Send to

Choose Destination
World J Urol. 2018 Dec 13. doi: 10.1007/s00345-018-2598-7. [Epub ahead of print]

Predictors of thrombosis in testicular cancer during platinum-based chemotherapy.

Author information

1
Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
2
Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
3
Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.
4
Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University Hospital Cologne, Kerpener Straße 62, 50937, Cologne, Germany. axel.heidenreich@uk-koeln.de.

Abstract

PURPOSE:

To identify potential risk factors for the development of venous thromboembolic events in testicular cancer patients receiving platinum-based chemotherapy.

METHODS:

We performed a retrospective analysis including 255 patients with testicular germ cell tumors who received platinum-based chemotherapy from 2003 to 2018 as a multi-center observational cohort study. Patient and tumor characteristics of patients with and without a thromboembolic event were analyzed.

RESULTS:

49 (19%) patients experienced a venous thromboembolic event, with the majority representing pulmonary embolism and deep venous thrombosis (47%). There were no significant differences regarding the development of a venous thromboembolic event between first- and second-line regimes. Multivariate analysis showed an increased risk for a venous thromboembolic event in patients with clinical stage ≥ IIC disease (OR 2.259 [95% CI 1.105-4.618], p = 0.026), elevated serum LDH (OR 2.162 [95% CI 1.018-4.593], p = 0.045), febrile neutropenia (OR 2.973 [95% CI 1.363-6.487], p = 0.006) and central venous access (OR 3.465 [95% CI 1.068-11.243], p = 0.039). Patients suffering from a venous thromboembolic event revealed a significantly reduced overall survival (p = 0.033) during a median follow-up of 8 months [IQR 2-18].

CONCLUSIONS:

19% of all patients treated by platinum-based chemotherapy due to testicular cancer suffered from a venous thromboembolic event, associated with reduced overall survival. As a result, monitoring of cancer patients at risk as well as the improvement of patients' awareness of a thromboembolic event should thus be the main goal of their treating physicians.

KEYWORDS:

Chemotherapy; Cisplatin; Germ cell tumor; Thrombosis

PMID:
30547197
DOI:
10.1007/s00345-018-2598-7

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center